BMS revises hepatitis B therapy warning label
James G. Dickinson
October 01 2007
The FDA reports that Bristol-Myers Squibb has revised hepatitis B therapy Baraclude's boxed warning labeling to caution against its use ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.